Home / Themes / Healthcare '24: Women's & Reproductive Health

Healthcare '24: Women's & Reproductive Health (open on stockthemes)

Last updated

Theme thesis · 3/5 sections · Tickers 3 with notes · 8 pending

Loading chart…
Loading…

Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).

Bull / Bear Details

Women's and reproductive healthcare companies develop and commercialize contraceptives, treatments for gynecological conditions, prenatal genetic screening, mat

Thesis

Women's and reproductive healthcare companies develop and commercialize contraceptives, treatments for gynecological conditions, prenatal genetic screening, maternal-risk diagnostics and specialized reproductive-health technologies. The theme captures pregnancy prevention, endometriosis and uterine fibroid treatments, fetal chromosomal screening, preterm-birth risk assessment and gynecological disease detection. Economic drivers include contraceptive utilization, diagnostic testing volumes, insurance coverage, clinical adoption of new treatment methods and improved maternal-health management. Fertility treatment and IVF are primarily covered in the separate MedTech Fertility & Assisted Reproductive Technologies theme.

Bull case

  • Expanded access to long-acting and nonhormonal contraception increases patient choice and supports adoption of new intrauterine, vaginal and nonsurgical permanent birth-control technologies.

  • Advances in cell-free DNA screening, proteomic pregnancy-risk testing and maternal-fetal imaging improve early identification of pregnancy complications, supporting greater prenatal testing utilization and payer coverage.

  • New pharmaceutical treatments and specialized diagnostics for endometriosis, uterine fibroids, vaginal health and gynecological disease address historically underserved conditions and expand opportunities beyond routine reproductive care.

Bear case

  • Contraceptive products and gynecological therapies face regulatory delays, safety concerns, adverse-event litigation and patient resistance to hormonal or invasive treatments, potentially restricting adoption and product availability.

  • Prenatal genetic screening and maternal-risk testing face reimbursement restrictions, pricing competition and changing medical guidelines, while uncertain evidence of improved clinical outcomes can slow payer and physician adoption.

  • Development-stage reproductive-health companies face clinical trial failures and financing challenges, while pharmaceutical generics and competition among diagnostic laboratories reduce pricing power for established therapies and screening products.

Overview

Hiring Trend Watchpoints

High-performing operators in this theme show a decisive hiring shift away from broad primary-care commercial forces toward specialized OB/GYN practice educators, certified procedural trainers, and regional market access liaisons. For device and contraceptive innovators like Organon, Femasys, and Daré Bioscience, expanding job postings for field clinical specialists and REMS compliance coordinators confirm commercial readiness for in-office procedures (such as MIUDELLA insertion training and FemBloc pivotal trial site support). In prenatal and maternal diagnostics (Natera, Sera Prognostics), top operators are stabilizing or reducing routine administrative and manual genetic counseling headcount via workflow AI and automated billing cycle management, while aggressively hiring health-economics and outcomes research (HEOR) and government-affairs specialists to secure state Medicaid and commercial payer coverage mandates. A freeze in OB/GYN sales expansions or rising turnover in payer-relations teams serves as an early warning of commercialization friction and ASP erosion.

Forum Watchlist

  • reddit — r/birthcontrolHigh

    Real-world consumer demand, side-effect sentiment, and provider access bottlenecks for next-generation contraceptives including MIUDELLA, Ovaprene clinical trials, and non-hormonal IUD options.

  • reddit — r/EndoHigh

    Patient sentiment, therapeutic adherence, and insurance prior-authorization barriers for oral GnRH antagonists (Orilissa, Oriahnn) versus surgical excision.

  • reddit — r/NIPTHigh

    Clinical utility and patient reception of cell-free DNA prenatal screens (Panorama, Prequel), low fetal fraction no-call rates, and microdeletion false-positive disputes.

  • reddit — r/BabyBumpsMedium

    Expectant mother awareness and physician recommendations for maternal risk biomarkers, preterm birth blood tests (PreTRM), and maternal-fetal ultrasound imaging.

  • medical_community — Student Doctor Network - OB/GYN ForumMedium

    Physician discussion regarding in-office procedural adoption (FemBloc vs surgical tubal ligation, FemaSeed vs IVF), REMS certification burden, and diagnostic lab test ordering habits.

Industry Publications

  • Contemporary OB/GYN (contemporaryobgyn.net) — Authoritative trade journal covering clinical trial readouts, FDA approvals for contraceptives and endometriosis treatments, and ACOG guideline updates.
  • The American Journal of Obstetrics & Gynecology (ajog.org) — Leading peer-reviewed journal publishing landmark clinical data on maternal-fetal medicine, preterm birth biomarkers, prenatal diagnostics, and gynecologic surgery.
  • GenomeWeb (genomeweb.com) — In-depth coverage of molecular diagnostics, noninvasive prenatal testing (NIPT) innovations, FDA LDT regulations, and MolDx reimbursement determinations.
  • Femtech Insider (femtechinsider.com) — Specialized publication tracking women's reproductive health biotechnology, fertility medical devices, licensing transactions, and commercial product launches.
  • Contraceptive Technology Update (reliasmedia.com) — Specialized monthly newsletter providing clinical practice insights, contraceptive efficacy metrics, IUD placement protocols, and family planning regulatory developments.

Second Order Trends

1. Nonhormonal and Low-Dose Contraceptive Pivot: A growing consumer and clinical shift away from systemic synthetic hormones is driving rapid pipeline advancement for hormone-free options, evidenced by Organon licensing and launching MIUDELLA, Daré advancing Ovaprene through Phase 3, and Femasys pursuing non-surgical occlusion with FemBloc. 2. In-Office Procedural Decentralization: Reproductive care is shifting out of outpatient surgical centers and specialized fertility clinics directly into general OB/GYN offices, lowering patient costs for permanent birth control and first-line fertility treatments (e.g., FemaSeed). 3. REMS and Physician Certification as Commercial Moats: Insertion complexity for novel intrauterine and tubal systems requires formal physician certification (e.g., MIUDELLA REMS), making provider training networks the primary competitive moat and speed-to-revenue determinant. 4. Maternal Preterm Risk Testing Scaling into State Payers: Diagnostic testing is expanding beyond fetal chromosomal aneuploidy into proteomic risk prediction for spontaneous preterm birth (Sera's PreTRM), increasingly driven by state Medicaid legislative mandates. 5. Portfolio Carve-Outs and Focused Specialization: Molecular diagnostic players are optimizing capital allocation by divesting commoditized prenatal testing lines (e.g., Myriad's sale to Labcorp) to concentrate on oncology, leaving scale winners like Natera to leverage superior low-fetal-fraction testing moats.

Search Keywords Brand Product

  • MIUDELLA
  • Ovaprene
  • FemBloc
  • FemaSeed
  • Panorama
  • PreTRM
  • Nexplanon
  • NuvaRing
  • Paragard
  • Mirena
  • Kyleena
  • Orilissa
  • Oriahnn
  • FirstGene
  • Prequel
  • Foresight
  • Ova1
  • Overa
  • Voluson
  • DARE-HPV
  • women's reproductive health
  • hormone-free contraception
  • nonhormonal birth control
  • long-acting reversible contraception
  • noninvasive prenatal testing
  • maternal fetal medicine
  • preterm birth biomarker
  • endometriosis pain management
  • uterine fibroids
  • nonsurgical permanent contraception

Search Keywords Policy Regulatory

  • modular PMA submission
  • FDA Premarket Approval
  • Risk Evaluation and Mitigation Strategy
  • REMS certification
  • ACOG clinical practice guidelines
  • Society of Family Planning guidelines
  • Medicaid maternal health coverage mandate
  • MolDx local coverage determination

Search Keywords Event Phrases

  • Society of Family Planning Annual Meeting
  • ACOG Annual Clinical Meeting
  • SMFM Pregnancy Meeting
  • Ovaprene Phase 3 study readout
  • FemBloc FINALE trial enrollment
  • MIUDELLA commercial availability

Google Trend Product Category Intent

• Miudella IUD • Ovaprene • FemBloc • FemaSeed • Panorama test • PreTRM test • Orilissa • Paragard IUD • Mirena IUD • Nexplanon implant

Google Trend Consumer Intent

• non hormonal birth control • best copper IUD • IUD insertion pain relief • NIPT test accuracy • preterm birth risk test • endometriosis pain treatment • tubal ligation alternatives • permanent birth control without surgery

Google Trend Macro Policy Terms

• Medicaid IUD coverage • ACOG prenatal screening recommendations • FDA nonhormonal birth control approval • maternal mortality healthcare policy

Economic Data Watch

1. FRED — Personal Consumption Expenditures

Matchedfred · access=api · map_only

Metric/field PCEPI

Cadence monthly

Why it matters Overall healthcare spending indicates the market size and health for diagnostic services and treatments, directly impacting the addressable market for the theme's companies.

Signal to watch Increasing personal consumption expenditures on healthcare is bullish.

Confidence: high

2. CDC / NCHS — National Vital Statistics System

Not in registry

Metric/field Birth Rate (per 1,000 population)

Cadence annually

Why it matters A fundamental driver for prenatal care, maternal health, and contraception product demand, directly impacting the revenue potential for companies in these segments.

Signal to watch Stable or increasing birth rates are bullish for prenatal and maternal health segments.

Confidence: high

3. CMS — National Health Expenditure Accounts

Not in registry

Metric/field Total Health Expenditures

Cadence annually

Why it matters Provides a comprehensive view of the overall healthcare market size, influencing investment and growth opportunities for companies in the theme.

Signal to watch Increasing total health expenditures indicate a growing market.

Confidence: high

4. BLS — Consumer Price Index

Not in registryaccess=api

Metric/field CUUR0000SAM2

Cadence monthly

Why it matters Inflation in medical care services can impact the profitability of healthcare providers and, by extension, the pricing and reimbursement for products and services offered by companies in this theme.

Signal to watch Stable or increasing medical care services CPI is generally bullish for pricing power.

Confidence: high

5. CMS — National Health Expenditure Accounts

Not in registry

Metric/field Federal Government Health Consumption Expenditures and Gross Investment

Cadence annually

Why it matters Government spending, particularly through Medicare and Medicaid, significantly influences reimbursement policies and market access for diagnostic tests and treatments within the theme.

Signal to watch Increased government healthcare spending or favorable policy changes are bullish.

Confidence: high

Free Alt Data Watch

1. ClinicalTrials.gov — Study Records

Not in registry

Metric/field Overall Status, Enrollment, Primary Completion Date

Cadence event_driven

Why it matters New clinical trials and progress in existing ones signal future product pipeline strength and potential market introductions for companies developing new treatments and diagnostics.

Signal to watch Increasing number of trials, faster enrollment, and positive completion statuses are bullish.

Confidence: high

2. FDA — Drug Approvals / Device Clearances

Not in registry

Metric/field Approval Date, Product Name, Therapeutic Area (drugs); Decision Date, Device Name, Product Code (devices)

Cadence daily

Why it matters Regulatory approvals are critical milestones for commercialization and revenue generation for pharmaceutical and medical device companies within the women's and reproductive health space.

Signal to watch Increased approvals for relevant products are bullish.

Confidence: medium

3. Google Trends — Search Interest

Not in registry

Metric/field Search volume index for "prenatal screening", "contraception options", "endometriosis treatment", "IVF success rates"

Cadence daily

Why it matters Reflects public awareness and potential demand for products and services within the theme, indicating shifting patient interest and market trends.

Signal to watch Increasing search interest in these terms is bullish for related companies.

Confidence: high

4. USPTO PatentsView — Patent Grants / Applications

Not in registry

Metric/field Number of patents granted/applications filed for CPC codes related to reproductive health technologies (e.g., A61B17/42, A61K31/56)

Cadence monthly

Why it matters Patent activity indicates innovation and competitive positioning, offering insights into future product development and market leadership.

Signal to watch Increased patent grants or applications by theme companies or in relevant technology areas are bullish.

Confidence: medium

5. Company Careers Pages — Job Postings

Not in registry

Metric/field Number of job postings for R&D, sales, and clinical roles

Cadence weekly

Why it matters Hiring trends, especially in R&D, sales, and clinical functions, can signal a company's investment in growth, product development, and market expansion.

Signal to watch Increasing job postings in key growth areas are bullish.

Confidence: medium

Paid Alt Data Watch

1. IQVIA — Medical Claims Data

Matchediqvia_medical_claims · access=file · map_only

Metric/field CPT code utilization for prenatal screening (e.g., 81420, 81507), contraception (e.g., J7300, J7302), and endometriosis treatments (e.g., J1950)

Cadence monthly

Why it matters Provides granular, independent data on actual test and treatment utilization, market share, and reimbursement trends for products within the theme.

Signal to watch Increasing utilization and favorable reimbursement trends are bullish.

Confidence: high

2. Symphony Health — Prescription Data

Not in registry

Metric/field New and total prescriptions for key contraceptive brands (e.g., Nexplanon, NuvaRing, Mirena, Kyleena) and gynecological therapies (e.g., Orilissa, Oriahnn)

Cadence weekly

Why it matters Directly measures the adoption and market penetration of pharmaceutical products, offering real-time insights into sales performance and competitive dynamics.

Signal to watch Increasing prescription volumes for theme-relevant products are bullish.

Confidence: high

3. HealthVerity — Multi-source / Aggregated Claims Data

Matchedhealthverity_lab_data · access=file · map_only

Metric/field Patient journey analytics for specific conditions (e.g., endometriosis, preterm birth, infertility) including diagnosis rates, treatment pathways, and recurrence rates

Cadence monthly

Why it matters Offers deep insights into patient populations, disease progression, and treatment effectiveness, which can inform market sizing and product development strategies.

Signal to watch Favorable patient journey trends (e.g., earlier diagnosis, effective treatment retention) are bullish.

Confidence: high

4. Clarivate Life Sciences & Healthcare — Drug & Device Pipeline Intelligence

Matchedclarivate_life_sciences_drug_intelligence · access=file · map_only

Metric/field Phase progression, trial results, and regulatory submission timelines for investigational drugs and devices in women's and reproductive health

Cadence daily

Why it matters Provides early intelligence on the competitive landscape and future market entrants, crucial for assessing long-term growth prospects and risks.

Signal to watch Positive pipeline advancements and successful trial readouts are bullish.

Confidence: high

5. SmartTRAK — Medical Device Market Data

Matchedsmarttrak_medical_device_market_share_sales_intelligence · access=file · map_only

Metric/field Market share, sales volumes, and pricing trends for gynecological instruments, IVF equipment, and contraceptive devices (e.g., IUDs, implants)

Cadence monthly

Why it matters Offers detailed market insights into the medical device segment of the theme, including competitive dynamics and product adoption rates.

Signal to watch Increasing market share and sales volumes for theme-relevant devices are bullish.

Confidence: high

Prediction Market Watch

1. Will Trump make IVF free? (Before his term ends)

Kalshi · Confidence: high

Not in registryaccess=api

Market https://kalshi.com/markets/kxfreeivf

Why it matters A policy decision to make IVF free would significantly impact companies within the Women's & Reproductive Health theme that are involved in assisted reproduction technologies, such as Femasys (FemaSeed fertility devices) and CooperSurgical (IVF equipment operations). Increased access and potential government funding for IVF could drive higher demand for their products and services, leading to substantial revenue growth. Conversely, if IVF is not made free, the current market dynamics and reimbursement challenges would persist.

Series key pm_ivf_free_policy

Theme Plain English
This theme captures companies developing and commercializing therapeutic, diagnostic, and medical device solutions dedicated to women's reproductive health and maternal-fetal care. Core exposures span next-generation contraception (hormone-free and long-acting devices, nonsurgical permanent birth control), maternal and prenatal genetic screening (cell-free DNA, chromosomal aneuploidy, and preterm birth risk testing), and targeted therapies addressing historically underserved gynecological diseases such as endometriosis, uterine fibroids, and ovarian cancer risk.
Upcoming Catalysts6 rows
Catalyst IDEstimated TimingEstimated Date StartEstimated Date EndCatalystWhy It MattersTicker Or Theme SpecificTranscript DateSource TypeCatalyst Source
ABBV_c5da1469later this year2026-10-012026-12-31US regulatory approval decision for RINVOQ for the treatment of vitiligo.This approval would mark RINVOQ as the first systemic treatment for vitiligo, significantly expanding its market potential and contributing to the anticipated combined peak sales of $2 billion for vitiligo and alopecia areata indications.Ticker2026-07-31earnings_transcriptABBV (ticker)
NTRA_be394610later this year2026-10-012026-12-31Commercial launch of Signatera for colorectal cancer in Japan.This launch is expected to drive market adoption and revenue in Japan, supported by existing society guidelines.Ticker2026-08-06earnings_transcriptNTRA (ticker)
NTRA_c9201351later this year2026-10-012026-12-31Commercial launch of Signatera for colorectal cancer in Japan, pending final pricing and reimbursement determination.This represents a significant international market expansion for Signatera, potentially driving substantial revenue growth and solidifying its global footprint in oncology diagnostics.Ticker2026-08-06earnings_transcriptNTRA (ticker)
MYGN_455de998by early 2027, with an outside date of Feb 19, 20272027-01-012027-02-19Closing of the definitive agreement to sell Myriad's Prenatal Health business to Labcorp.This transformational transaction is expected to significantly improve Myriad's financial profile, including revenue growth, profitability, and liquidity, by allowing the company to focus on the Cancer Care Continuum.Ticker2026-11-04earnings_transcriptMYGN (ticker)
MYGN_3a65a078Q1 of 20272027-01-012027-03-31Full commercial launch of Precise MRD.This represents the broader commercialization of the Precise MRD platform, significantly expanding its market reach and revenue potential across multiple cancer types.Ticker2026-05-05earnings_transcriptMYGN (ticker)
NTRA_cb105215at the JPMorgan conference, if not sooner2027-01-012027-01-31Update on reimbursement and pricing for the commercial launch of Signatera for colorectal and muscle-invasive bladder cancer in Japan.Finalizing reimbursement and pricing is critical for the commercial launch of Signatera in Japan, a significant international market with high colorectal cancer prevalence, potentially leading to accretive ASPs.Ticker2026-11-05earnings_transcriptNTRA (ticker)

Loading correlation…

Constituents

  • — AbbVie Inc.
  • — Myriad Genetics, Inc.
  • — Natera, Inc.
  • AWHLT3
    · no notes yet
  • BAYN.XETRAT3
    · no notes yet
  • COOT3
    · no notes yet
  • DARET3
    · no notes yet
  • FEMYT3
    · no notes yet
  • GEHCT3
    · no notes yet
  • OGNT3
    · no notes yet
  • SERAT3
    · no notes yet